A Phase 2 interventional study of Tamoxifen 20 mg and Anastrozole 1Mg Tab in Ductal Carcinoma in Situ, Extensive Disease and Mastectomy, sponsored by Institut Cancerologie de l'Ouest. Recruiting at 8 sites in France. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-04-22.
Sponsored by Institut Cancerologie de l'Ouest · Phase 2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating — 4 open to participants now, 6 under way, 3 of them phase 3. Tamoxifen · Carcinoma, Intraductal, Noninfiltrating.
Among the 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 12th registered.
287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.
Browse Carcinoma, Intraductal, Noninfiltrating studies →4 of the 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating are open now, in 3 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 45–74 · Women only · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 18–55 · Women only
National Taiwan University Hospital · Sites in Taiwan
Ages 40+ · Women only
By country, each count listing its studies:
Tamoxifen: first FDA approval 1977 (NOLVADEX). What it is approved for, and how studies give it, is on its page →
Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 40 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 5
First in 2000; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 262 is above the median of 66 across 209 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.
Median enrollment 262 across the 15 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
Institut Cancerologie de l'Ouest is the lead sponsor of 109 studies on the registry; 20 are open to participants now.
Institut Cancerologie de l'Ouest has 1 study filed under Carcinoma, Intraductal, Noninfiltrating — fewer than ten, so there is no comparison to draw.
1 of the studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06195306National Cancer Institute (NCI)Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most often manifest as diffuse microcalcifications.
This mutilating surgical management contrasts with the excellent prognosis of this pathology and considerably alters the quality of life of patients.
Neoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal carcinomas and offers the possibility of conservative surgery after hormone therapy.
Adjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the prevention of homo or contralateral recurrence.
The HORNEO 01 trial fits perfectly in the current context of surgical de-escalation of ductal carcinomas in situ. The objective of the study is to evaluate the impact of neoadjuvant hormone therapy on the surgical management of extensive DCIS.
Description of the modalities for recruiting :
Following screening and discovery of a DCIS, patients are referred to the center for surgical management.
During a standard consultation, the surgeon presents the study to the patient who has been diagnosed with extensive DCIS with an indication for mastectomy. The surgeon provides the patient with the information note and the consent form to participate in the study. Once the consent form is signed by the patient and the investigator, the investigator prescribes a screening test to be performed within 30 days prior to the start of hormone therapy.
Screening assessment includes :
A clinical exam and a breast imaging exam (mammography and breast and axillary ultrasound). In case of a suspicious breast ultrasound image, microbiopsy will be performed to eliminate an infiltrating component.
One or more macrobiopsy. Each biopsied site will be located using an X-ray clip inserted at the time of sample.
A MRI post-macrobiopsy. Research of estrogen receptor expression
Once the investigator has verified and validated all the eligibility criteria, the patient will be included.
Prescriptions for Tamoxifen (non-menopausal patients) or Anastrozole (menopausal patients) are given to patients and dispensed by the center's pharmacy.
Monitoring during treatment :
Patients will benefit from imaging monitoring (Mammography, +/- breast ultrasound, +/- axillary ultrasound, MRI) at 3 months and 6 months during hormonotherapy.
In case of progression observed during treatment, hormone therapy will be stopped and you will then benefit from a mastectomy.
Surgery :
Mastectomy or tumorectomy will be performed according to the tumor response to hormone therapy observed on MRI.
All patients will benefit sentinel node detection. An additional axillary dissection will be performed based on the results of the sentinel node analysis.
Analysis of biomarkers and tumor microenvironment before and after treatment on diagnostic macrobiopsies and on tumorectomy or mastectomy will be performed at Institut de Cancérologie de l'Ouest.
Patients will be seen in postoperative consultation. Adjuvant treatments or re-surgical interventions will be prescribed, carried out, and the patients will be followed up and examined at 6 months after surgery or at the end of adjuvant treatments and then annually for 10 years (with control mammography).
Patients who have had conservative surgery will have an MRI at 6 months from the end of radiotherapy.
All patients will be asked to complete quality of life questionnaires at baseline, 6 and 12 months post-surgery, and annually for 9 years:
EORTC QLQ-C30 (up to 5 years only), Short Form (36) Health Survey questionnaire.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive 6 months of tamoxifen or anastrozole in a neoadjuvant situation. Tamoxifen and Anastrozole will be delivered in their original packaging at J0 and M3 : * Tamoxifen: box of tablets dosed at 20 mg * Anastrozole: box of tablets 1 mg. Tamoxifen will be initiated in premenopausal patients orally at a standard dose of 20mg/day as a single dose for 6 months. Anastrozole will be administered orally to postmenopausal patients at the standard dose of 1mg/day in a single dose for 6 months.
Drug: Tamoxifen 20 mg · Drug: Anastrozole 1Mg Tab
Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
Efficacy of neoadjuvant hormonotherapy
% of conservative surgeries performed after hormonotherapy
Time frame: 6 months of hormonotherapy
Disease-free survival (DFS)
DFS rates at 5 and 10 years post-surgery
Time frame: 5 and 10 years post-surgery
Overall survival (OS)
Survival rates at 5 and 10 years post-surgery
Time frame: 5 and 10 years post-surgery
Pathologic Complete Response (pCR)
Pathologic complete response is defined as no residual invasive cancer in the surgical specimen
Time frame: 6 months of hormonotherapy
Predictive factors of response
Response is defined by the variation in the diameter of the longest dimension of the target lesion measured by MRI
Time frame: 3 and 6 months of hormonotherapy
Quality of Life (Qol)
EORTC QLQ-C30 questionnaire
Time frame: At baseline, at 6 months and 12 months post-surgery, and then each year for 4 years
Quality of Life (Qol)
SF-36 questionnaire
Time frame: At baseline, at 6 months and 12 months post-surgery, and then each year for 9 years
Started Feb 2021 (actual). Primary completion is estimated for Aug 2024, 41 months after the start.
Of 36 phase 2 interventional studies under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 170. This study's planned 41 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tamoxifen · Anastrozole
Carcinoma, Intraductal, Noninfiltrating →
Institut Cancerologie de l'Ouest →